



Report ▶ Repeat ▶ Revise

# Product Data - D12079B

## Description

RD Western Diet

## Used in Research

- Obesity
- Diabetes
- Osteoporosis
- Hypertension
- Atherosclerosis
- Metabolic Syndrome

## Packaging

Product is packed in 12.5 kg box.  
Each box is identified with the product name, description, lot number and expiration date.

## Lead Time

D12079B in 5-7 business days.

## Gamma-Irradiation

D12079Bi available on request.  
Add 10 days to delivery time.

## Form

Pellet, Powder, Liquid

## Shelf Life

Most diets require storage in a cool dry environment. Stored correctly they should last 6 months.

## Control Diets

Custom diets available on request.

## Formula

Product # D12079B	gm%	kcal%
Protein	20	17
Carbohydrate	50	43
Fat	21	40
<b>Total kcal/gm</b>	<b>4.7</b>	<b>100</b>

  

Ingredient	gm	kcal
Casein, 80 Mesh	195	780
DL-Methionine	3	12
Corn Starch	50	200
Maltodextrin 10	100	400
Sucrose	341	1364
Cellulose	50	0
Milk Fat, Anhydrous*	200	1800
Corn Oil	10	90
Mineral Mix S10001	35	0
Calcium Carbonate	4	0
Vitamin Mix V10001	10	40
Choline Bitartrate	2	0
Cholesterol, USP*	1.5	0
Ethoxyquin	0.04	0
<b>Total</b>	<b>1001.54</b>	<b>4686</b>

\*Anhydrous milk fat typically contains approximately 0.3% cholesterol. On this basis, D12079B contains approximately 0.21% cholesterol. Formulated by E. A. Ulman, Ph.D., Research Diets, Inc., October 12, 1995. Diet formulated to match Teklad Western Diet #TD88137, except that 1% Corn Oil replaces 1% Butter Fat.



Where NutriPhenomics Begins





## References - D12079B

Report ▶ Repeat ▶ Revise

1. Beigneux, A.P., et al. ATP-Citrate lyase deficiency in the mouse. *Journal of Biological Chemistry*. 279:9557-9564, 2004.
2. Bhat, B.G. et al. Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE<sup>-/-</sup> mice by SC-435. *Journal of Lipid Research*. 44:1614-1621, 2003.
3. Collins, A.R. et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. *Arterioscler Thromb. Vasc. Biol.* 21:365-371, 2001.
4. Davis, H.R., et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibit the development of atherosclerosis in ApoE knockout mice. *Arterioscler Thromb. Vasc. Biol.* 21:2032-2038, 2001.
5. Lemaître, V., et al. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. *Circulation*. 107:333-338, 2003.
6. Lemaître, V. et al. ApoE knockout mice expressing human matrix metalloproteinase-1 macrophages have less advanced atherosclerosis. *Journal of Clinical Investigation*. 107:1227-1234, 2001.
7. Ogus, S. et al. Hyperleptinemia precipitates diet-induced obesity in transgenic mice overexpressing leptin. *Endocrinology*. 144:2865-2869, 2003.
8. Park, Tae-Sik, et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. *Circulation*. 110:3465-3471, 2004.
9. Seli, E., et al. Estradiol suppresses vascular monocyte chemotactic protein-1 expression during early atherogenesis. *Am. J. Obstet. Gynecol.* 187:1544-1549, 2002.